drugset
drugset / Trial / NCT04332432

GT-032 Belapectin Hepatic Impairment

NCT04332432 ↗

Phase 1 Completed 38 enrolled Galectin Therapeutics Inc.
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study will assess the pharmacokinetics of belapectin in subjects with mild, moderate, or severe hepatic impairment according to 3 different Child-Pugh categories: mild, moderate, or severe impairment, compared to matched healthy control subjects.

Timeline

Start
2020-06-16
Primary completion
2022-03-09
Completion
2022-03-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator belapectin Other / unclassified — Intravenous

Indications

No indication recorded.